What is it, and why does it matter? Vizz (aceclidine ophthalmic solution) is a new prescription eye drop approved to treat presbyopia, a common condition that makes it harder to see things up close as ...

Please provide your email address to receive an email when new articles are posted on . Patients improved visual acuity across three concentrations of pilocarpine. Adverse events were mild and ...

The first aceclidine-based eye drop to improve near vision in adults with presbyopia, which affects more than 100 million adults in the US alone, has been approved by the Food and Drug Administration ...

Credit: Lenz Therapeutics. Vizz eye drops contain a cholinergic muscarinic agonist that causes contraction of the iris sphincter muscle, resulting in a pinhole effect that extends focus depth to ...

Lenz Therapeutics said on Wednesday its lead experimental drug being tested in patients with a common age-related eye disorder showed improvement in nearsightedness in a late-stage study. Shares of ...

A new eye drop, Vizz, was recently FDA approved and is helping people regain near vision without glasses. Originally used for glaucoma, the drops are now repurposed for presbyopia (age-related ...

End Of Reading Glasses?: Bad lifestyle and lack of nutrition in diet have affected our overall health, its effect is being seen on the health of eyes as well. Apart from this, constantly being glued ...

Share on Pinterest Scientists have developed new eye drops that could help with presbyopia. Ekaterina Vasileva-Bagler/Getty Images Researchers estimate that about 1.8 billion people around the world ...

For millions of adults, aging brings a familiar frustration: difficulty focusing on close-up objects such as books, smartphones, or small print. Traditionally, reading glasses or surgery have been the ...

Glaucoma occurs due to optic nerve damage. A common treatment is prescription eye drops. Although eye drops do not cure or reverse vision loss, they can help prevent optic nerve damage. Glaucoma ...

April 3 (Reuters) - Lenz Therapeutics (LENZ.O), opens new tab said on Wednesday its lead experimental drug being tested in patients with a common age-related eye disorder showed improvement in ...